Gilead Science公司在2025年的Q2比预期的收入高,提高了全年的指导水平,并宣布了红利,尽管内部销售和股票下跌。 Gilead Sciences beat earnings expectations in Q2 2025, raised full-year guidance, and declared a dividend, despite insider sales and a stock dip.

2025年,Gilead Science公司报告收入丰厚,其收入为2.47 EPS和77.7亿美元,超过预期,并将2025年全年指导提高到每股8.05至8.25美元。 In Q2 2025, Gilead Sciences reported strong earnings with $2.47 EPS and $7.77 billion in revenue, exceeding expectations, and raised its 2025 full-year guidance to $8.05–8.25 per share. 该公司宣布季度红利为0.79美元,收益2.5%,内幕销售总额115 146股,价值1 400万美元,包括首席执行官Daniel Patrick O'Day和Johanna Mercier的销售。 The company announced a quarterly dividend of $0.79, yielding 2.5%, and saw insider sales totaling 115,146 shares worth $14 million, including sales by CEO Daniel Patrick O’Day and Johanna Mercier. 机构投资者减少了股份,斯科舍省资本、Schroder和四级咨询服务公司对股份进行减量。 Institutional investors reduced stakes, with Scotia Capital, Schroder, and Level Four Advisory Services trimming holdings. 尽管本季度股票下跌了11.2%,但Gilead的股票交易额为125.85美元,市场上限为156.13亿美元,共识为“Moderate Buy”评级。 Despite a 11.2% stock decline during the quarter, Gilead’s shares traded at $125.85, with a market cap of $156.13 billion and a consensus “Moderate Buy” rating.